Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Aimmune Therapeutics

Thumbnail
December 14, 2020

Astrazeneca rescues biopharma's 2020 takeover scorecard

Thumbnail
October 07, 2020

Gilead rescues biopharma’s takeout scene

A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.

Article image
Vantage logo
September 01, 2020

Nestlé pays $2.6bn to eat peanut player Aimmune

Article image
Vantage logo
August 04, 2020

DBV confirms the inevitable

Article image
Vantage logo
July 09, 2020

Biopharma shares shake off the pandemic

Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.

Article image
Vantage logo
April 17, 2020

Covid-19 adds a new danger to drug launches

Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.

Article image
Vantage logo
March 17, 2020

Regulatory pushback means DBV will struggle to stay in the peanut game

Article image
Vantage logo
February 03, 2020

US FDA approval tracker: a first for Aimmune

January saw Aimmune receive an FDA approval for Palforzia, a first for peanut allergy, alongside decisions for Blueprint Medicines and Horizon Therapeutics.

Article image
Vantage logo
January 21, 2020

Another blockbuster year looms for approvals

Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.

Article image
Vantage logo
December 23, 2019

Go or no go? Enhertu’s destiny revealed and FDA decisions due for Epizyme, Novo

Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.

Article image
Vantage logo
November 27, 2019

Investors see no end in sight to the misery of hayfever

Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.